errors are reflected in inaccurate diag nosis of the patient's dynamic psy chopathology, resulting in inaccurate diagnostic formulation, and in inef fective treatment planning and treat ment implementation.
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Metformin prescription in psychiatry
We thank Smith et al. for the publi cation of a metformin prescribing tool 1 for people with severe mental disorders (SMD). The importance of physical health in people with SMD is now well recognised. 2 Even though there is evidence to suggest that the rate of screening people with SMD for metabolic issues in Australia outperforms the interna tional average, the rate of interven tion still lags behind that of identification, 3 with physical ill health among those with SMD often underdiagnosed. 4 A practical tool to facilitate secondary prevention by limiting antipsychotic associated weight gain is of clear relevance to psychiatry.
There is further evidence that met formin may also have significant clin ical benefit even for those individuals who are already prescribed clozapine. A recent metaanalysis by Siskind et al. 5 found that people on metformin achieved significantly more weight loss compared to those on placebo. Given this, there is now a clinical trial in preparation in Queensland that is looking at the efficacy of metformin treatment in people with SMD.
It is relevant to highlight further some important issues associated with the prescription of metformin in psychiatry. First, there is the need for a comprehensive discussion with patients and their families about the implications of offlabel prescription, and a clear documentation of the rationale and the ongoing manage ment plan in the medical record. Furthermore, a registrar may require consultant approval before making an offlabel prescription. Attention to the inclusion in registrar training pro grammes regarding the practical use of metformin may be of great benefit.
Another issue we have seen debated for several years is whether the psychiatrist should take a lead role in chronic physical health interven tion or if this should be managed in primary care. While some psychia trists may argue for taking a proac tive interest in the physical health of our patients, others may see this as outside of our clinical expertise and professional comfort. This is an important issue we intend to fur ther explore in future. Nevertheless, the proposed metformin prescrib ing tool is a useful resource in assist ing psychiatrists and registrars to help address the persisting mortal ity and morbidity gaps among our patients.
